Trade BioLife Solutions Inc - BLFS CFD

BioLife Solutions, Inc. Company profile

About BioLife Solutions Inc

BioLife Solutions, Inc. is engaged in developing, manufacturing, and marketing bioproduction tools and services to the cell and gene therapy (CGT) industry. Its products are used in basic and applied research, and commercial manufacturing of biologic-based therapies. The customers use its products to maintain the health and function of biologic material during sourcing, manufacturing, storage, and distribution of cells and tissues. It has a portfolio of tools and services that focus on biopreservation, frozen storage, and thawing of biologic materials. Its product offerings under bioproduction tools and services include Biopreservation media, Automated thawing devices, Cloud connected smart shipping containers, Freezer and storage technology and related components, and Biological and pharmaceutical material storage. Its Biopreservation media products consists of HypoThermosol FRS and CryoStor. Its Astero ThawSTAR product line includes automated vial and cryobag thawing products.

Financial summary

BRIEF: For the twelve months ended 31 December 2021, BioLife Solutions Inc revenues increased from $35.9M to $119.2M. Net loss decreased 57% to $8.4M. Revenues reflect Product revenue increase from $32.8M to $101.9M, Service revenue increase from $1.8M to $9.8M, Rental revenue increase from $1.4M to $7.4M. Lower net loss reflects Change in fair value of warrant liab. decrease of 99% to $121K (expense).

Equity composition

Common Stock $.001 Par, 02/11, 100M auth., 69,679,854 issd. Insiders control 70.67%. IPO 11/89, 1M units (5 Common + 5 Class A Warrants) at $5/unit by D.H. Blair & Co. Preferred Stock $.001 Par, 12,080 auth., 12,055 issd. 6/00, *9/02, Name changed from Cryomedical Sciences, Inc. 01/14, 1-for-14 Reverse stock split.